The researchers called for more work to discover specific exposures in patients with leukemia that lead to infections after treatment ends.
A history of leukemia therapy during childhood may be associated with an increased risk of infections, according to a recent study published by the Journal of Clinical Oncology.
The researchers aimed to investigate infectious risk in survivors of childhood leukemia by comparing the relative rate of infections of childhood leukemia survivors following the end of treatment and the general population.
A retrospective, population-based cohort study was conducted with children diagnosed with leukemia between 1992 and 2015 who were alive and relapse free 30 days following treatment completion. The survivors were matched at a 5:1 ratio to the general population by birth year, sex, and urban/rural status and then stratified by initial treatment, including and excluding hematopoietic stem-cell transplantation (HSCT), according to the research.
In total, 2204 leukemia survivors were matched with 11,020 controls. Compared with controls, the rate of infections for survivors was higher after treatment completion and at less than 1 year, 1 to 4.99 years, and 5 or more years. Of those whose initial treatment excluded HSCT, the rate remained elevated more than 5 years after the treatment completion, the study found.
Additionally, the study found that infection-related death was significantly increased in all leukemia survivors, but also those without HSCT.
“An understanding of the risks for infection after therapy completion is important because it will guide recommendations for care during this period, including counselling for patients and families and re-immunization practices and medical care for leukemia survivors who present with signs or symptoms of infections,” the authors noted.
The researchers call for additional studies on this link between pediatric leukemia and infections. The studies should focus on establishing which specific exposures in patients with leukemia lead to infections later on, according to the research.
Reference
Pelland-Marcotte M, Pole J, Hwee J, et al. Long-term risk of infections after treatment of childhood leukemia: A population-based cohort study using administrative health data [published online August 8, 2019]. Journal of Clinical Oncology. doi.org/10.1200/JCO.19.00570
BrECADD Regimen Reaches “Unprecedently High” PFS for Patients With Hodgkin Lymphoma
June 18th 2024The treatment regimen not only significantly improved progression-free survival (PFS) for patients with advanced stage classic Hodgkin lymphoma but was also better tolerated compared with a 20-year-old regimen being used.
Read More
Lymphoma Research Foundation CEO on Biden’s Cancer Moonshot, Financial Toxicity
February 3rd 2022On this episode of Managed Care Cast, we speak with Meghan Gutierrez, CEO of the Lymphoma Research Foundation, about financial toxicity, how the pandemic has affected patients’ financial needs when they have cancer, health care disparities and care gaps, and more.
Listen
alloHSCT Yields Benefits in R/R AML Regardless of Leukemia Burden
December 22nd 2023Those with chronic graft-versus-host-disease who have received allogeneic hematopoietic stem cell transplant (alloHSCT) may experience enhanced graft-versus-leukemia effects, thus producing a lower relapse rate in acute myeloid leukemia.
Read More
Keeping Patients With Cancer Out of the ED Through Dedicated Urgent Care
October 13th 2021On this episode of Managed Care Cast, we bring you an interview conducted by the editorial director of OncLive® who talks with the advance practice provider chief at Winship Cancer Institute about how having a dedicated cancer urgent care center will make cancer treatment plans seamless whil helping patients avoid exposure to infectious diseases in emergency department waiting rooms.
Listen
Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies
December 11th 2023Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.
Read More